Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study

BMC Research Notes

Be-Nazir Ahmed¹  Ariful Basher²  Proggananda Nath³  Shah Golam Nabi⁴  A. F. M. Akhtar Hossain⁵  Md Golam Hasnain⁶  Shomik Maruf⁶  Dinesh Mondal⁶ 

[1]Co-ordination and Support Centre (CSC), Directorate General Health Services (DGHS), Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB)

[2]Critical Care Medicine (CCM), Bangabandhu Sheikh Mujib Medical University (BSMMU)

[3]Infection and Tropical Medicine, Mymensingh Medical College and Hospital (MMCH)

[4]Mugda Medical College and Hospital

[5]National Kala-azar Elimination Program (NKEP), Directorate General Health Services (DGHS), Ministry of Health and Family Welfare (MoHFW), Government of Bangladesh (GoB)

[6]Nutrition and Clinical Service Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

关键词: Treatment outcome;    Visceral leishmaniasis;    Amphotericin B deoxycholate;    Bangladesh;   

DOI  :  10.1186/s13104-018-4036-8

来源: DOAJ

【 摘 要 】

Abstract Objective Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh.

【 授权许可】

Unknown